Biogen’s expected filing for Alzheimer’s Drug aducanumab delayed until third quarter of 2020

The Phase III EMERGE trial met its primary endpoint, showing a significant decrease in clinical decline, and although there was still some skepticism about the overall data, it did appear to be enough to file a Biological License Application with the FDA.


Biospace Inc.